US FDA May Grant More Emergency Use Authorizations For COVID-19 Treatments This Fall
Executive Summary
Convalescent plasma, anti-inflammatory agents among those that could be considered for EUAs, Commissioner Hahn says during congressional hearing on the coronavirus response.
You may also be interested in...
US FDA Stays Out Of Hot Seat On COVID-19 Response – So Far
Commissioner Stephen Hahn was largely spared any direct criticism during a very long House hearing on COVID-19 response activities. That is a promising sign for the agency.
Convalescent Plasma Decision May Be ‘Week Or Two’ Away, US FDA’s Hahn Says
Commissioner says the agency is reviewing efficacy and safety data, presumably for an emergency use authorization of a product derived from patients who recovered from the virus.
Dexamethasone COVID-19 Findings Leave Authorities Bracing for Yet Another Demand Surge
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.